

Cristina Marcos-Arias

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2837706/publications.pdf>

Version: 2024-02-01

21
papers

643
citations

623574

14
h-index

610775

24
g-index

24
all docs

24
docs citations

24
times ranked

963
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>In vitro</i> and <i>in vivo</i> anti-<i>Candida</i> activity of citral in combination with fluconazole. Journal of Oral Microbiology, 2022, 14, 2045813.	1.2	5
2	In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, .	1.8	15
3	Development and Characterization of Monoolein-Based Liposomes of Carvacrol, Cinnamaldehyde, Citral, or Thymol with Anti- <i>Candida</i> Activities. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	10
4	In vitro activities of carvacrol, cinnamaldehyde and thymol against Candida biofilms. Biomedicine and Pharmacotherapy, 2021, 143, 112218.	2.5	24
5	Candida duobushaemulonii: An Old But Unreported Pathogen. Journal of Fungi (Basel, Switzerland), 2020, 6, 374.	1.5	7
6	Utility of two PCR–RFLP–based techniques for identification of Candida parapsilosis complex blood isolates. Mycoses, 2020, 63, 461-470.	1.8	3
7	Therapeutic tools for oral candidiasis: Current and new antifungal drugs. Medicina Oral, Patologia Oral Y Cirugia Bucal, 2019, 24, 0-0.	0.7	69
8	Oral Candida colonization in patients with chronic periodontitis. Is there any relationship?. Revista Iberoamericana De Micologia, 2018, 35, 134-139.	0.4	37
9	Antifungal Activity of the Human Uterine Cervical Stem Cells Conditioned Medium (hUCESC-CM) Against Candida albicans and Other Medically Relevant Species of Candida. Frontiers in Microbiology, 2018, 9, 2818.	1.5	16
10	Prevalence and antifungal susceptibility profiles of Candida glabrata, Candida parapsilosis and their close-related species in oral candidiasis. Archives of Oral Biology, 2018, 95, 100-107.	0.8	44
11	The continuous changes in the aetiology and epidemiology of invasive candidiasis: from familiar Candida albicans to multiresistant Candida auris. International Microbiology, 2018, 21, 107-119.	1.1	81
12	Usefulness of the Non-conventional Caenorhabditis elegans Model to Assess Candida Virulence. Mycopathologia, 2017, 182, 785-795.	1.3	24
13	In Vitro Antifungal Susceptibility of Oral Candida Isolates from Patients Suffering from Caries and Chronic Periodontitis. Mycopathologia, 2017, 182, 471-485.	1.3	12
14	Caries and <i>Candida</i> colonisation in adult patients in Basque Country (Spain). Mycoses, 2016, 59, 234-240.	1.8	17
15	Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis. Expert Review of Anti-Infective Therapy, 2013, 11, 347-358.	2.0	27
16	In Vitro Activities of New Triazole Antifungal Agents, Posaconazole and Voriconazole, Against Oral Candida Isolates from Patients Suffering from Denture Stomatitis. Mycopathologia, 2012, 173, 35-46.	1.3	20
17	Variation in biofilm formation among blood and oral isolates of Candida albicans and Candida dubliniensis. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2011, 29, 660-665.	0.3	11
18	Phospholipase and proteinase activities of Candida isolates from denture wearers. Mycoses, 2011, 54, e10-e16.	1.8	33

#	ARTICLE	IF	CITATIONS
19	In vitro activities of natural products against oral Candida isolates from denture wearers. BMC Complementary and Alternative Medicine, 2011, 11, 119.	3.7	90
20	Isolation of Candida dubliniensis in denture stomatitis. Archives of Oral Biology, 2009, 54, 127-131.	0.8	72
21	Usefulness of Candida ID2 agar for the presumptive identification of Candida dubliniensis. Medical Mycology, 2006, 44, 611-615.	0.3	21